Skip to Content
Merck Clinical Trials Logo

Clinical Trials

  • English
  • Español
Merck

Clinical Trials

Merck Clinical Trials Primary

  • About clinical trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs

Condition: Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

A Study of Vericiguat in Participants With Chronic Heart Failure With Reduced Ejection Fraction

November 12, 2021

By clique_admin

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Icon for accessibility